The TDF is a useful tool for grouping adherence barriers; patients have endorsed the relevance of literature-identified adherence barriers and provided useful anecdotes to further inform practice. Non-adherence to prescribed selleckchem medicines is of notable concern and a priority for pharmacy practice research. Whilst there is ample literature to report barriers to medication adherence in chronic conditions, a recent synthesis

of this literature is lacking, as is a cohesive, theory-based strategy for grouping medication adherence barriers. The Theoretical Domains Framework (TDF) is a composite of health psychology theory, designed to offer a structured approach for exploring the determinants of behaviour. Within this framework, key determinants of behaviour are grouped into behavioural domains such as skills, beliefs about capabilities and emotions.1 Medication Alpelisib adherence barriers were identified through a literature review and mapped to the behavioural domains of the TDF. University ethical approval was granted for the consultation exercises. Members of the public taking medicines for the prevention of cardiovascular disease (CVD) were purposively sampled from volunteers responding to a university-based recruitment strategy using

internal communication systems and social media that extended to the local community. The participants discussed the relevance of the literature-identified adherence barriers and the mapping of these to the TDF in two consultation exercises. These consultations Fludarabine concentration were audio-recorded, transcribed, and themed according to the behavioural domains of the TDF. Sixty medication adherence barriers were discussed across the following TDF behavioural domains; knowledge, skills, memory attention

and decision making processes, social influences, environmental constraints, emotions, motivation and goals, beliefs about consequences, beliefs about capabilities and the newly created goal conflicts. Two consultation exercises were undertaken, with five participants in the first and nine in the second. All participants were prescribed at least one medication for the prevention of CVD; the median number of medicines prescribed was 2 (IQR = 2–5). Eight (57%) participants were male and the median age was 66 (52 to 74) years. Participants understood the concept of grouping the adherence barriers according to the theoretical domains of the TDF and could relate the majority of the literature-identified barriers to their own experiences. The exceptions to this were barriers relating to fear of discrimination (emotions behavioural domain) and feeling embarrassed by taking medicines (social norms behavioural domain. Patient narratives provided an enhanced understanding about the ways in which medication adherence barriers can manifest.